NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68475-0503-01 | 68475-0503 | carmustine | Carmustine | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Dec 29, 2020 | In Use | ||
42291-0351-90 | 42291-0351 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 11, 2016 | Sep 1, 2018 | No Longer Used |
00085-1519-04 | 00085-1519 | Temozolomide | Temodar | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
69097-0313-37 | 69097-0313 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 200.0 mg/5mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 25, 2011 | In Use | |
72266-0253-01 | 72266-0253 | Cisplatin | CISPLATIN | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug 11, 2023 | In Use | |
68001-0313-56 | 68001-0313 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jul 1, 2017 | In Use | |
72205-0198-01 | 72205-0198 | Carmustine | Carmustine | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Nov 23, 2023 | In Use | ||
72819-0186-03 | 72819-0186 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 1, 2022 | In Use | |
16729-0048-54 | 16729-0048 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 7, 2017 | In Use | |
63304-0135-30 | 63304-0135 | Erlotinib | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Nov 5, 2019 | In Use | |
63304-0158-01 | 63304-0158 | Bromocriptine Mesylate | Bromocriptine Mesylate | 5.0 mg/1 | Chemotherapy | Dopamine Agonist | Ergot Derivative | Oral | Dec 22, 2016 | In Use | |
00074-0576-34 | 00074-0576 | Venetoclax | Venclexta | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BCL-2 | Oral | Nov 21, 2018 | In Use | |
00085-1430-04 | 00085-1430 | Temozolomide | Temodar | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
63323-0101-61 | 63323-0101 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jun 14, 2000 | In Use | |
63323-0103-51 | 63323-0103 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 5, 2000 | In Use | |
54868-5260-00 | 54868-5260 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jun 28, 2005 | In Use | |
63323-0103-64 | 63323-0103 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 5, 2000 | In Use | |
70771-1058-01 | 70771-1058 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb 9, 2017 | In Use | |
63323-0103-65 | 63323-0103 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 5, 2000 | In Use | |
00338-0720-01 | 00338-0720 | PEMETREXED | PEMETREXED | 100.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Aug 18, 2022 | In Use | |
61703-0408-41 | 61703-0408 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous | Feb 26, 2001 | In Use | |
00002-7623-01 | 00002-7623 | Pemetrexed disodium | Alimta | 500.0 mg/20mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Feb 13, 2004 | In Use | |
00003-0830-50 | 00003-0830 | Hydroxyurea | Hydrea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Jun 1, 2009 | Mar 31, 2025 | In Use |
00054-0481-13 | 00054-0481 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Feb 12, 2021 | In Use | |
51144-0001-60 | 51144-0001 | Tucatinib | TUKYSA | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Oral | Apr 17, 2020 | In Use |
Found 11120 results — Export these results